536 related articles for article (PubMed ID: 15245580)
1. Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma.
Bathe OF; Dowden S; Sutherland F; Dixon E; Butts C; Bigam D; Walley B; Ruether D; Ernst S
BMC Cancer; 2004 Jul; 4():32. PubMed ID: 15245580
[TBL] [Abstract][Full Text] [Related]
2. Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer.
Teufel A; Steinmann S; Siebler J; Zanke C; Hohl H; Adami B; Schroeder M; Klein O; Höhler T; Galle PR; Heike M; Moehler M
BMC Cancer; 2004 Jul; 4():38. PubMed ID: 15265233
[TBL] [Abstract][Full Text] [Related]
3. A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases.
Bathe OF; Ernst S; Sutherland FR; Dixon E; Butts C; Bigam D; Holland D; Porter GA; Koppel J; Dowden S
BMC Cancer; 2009 May; 9():156. PubMed ID: 19457245
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy.
Goéré D; Benhaim L; Bonnet S; Malka D; Faron M; Elias D; Lefèvre JH; Deschamps F; Dromain C; Boige V; Dumont F; De Baere T; Ducreux M
Ann Surg; 2013 Jan; 257(1):114-20. PubMed ID: 23235397
[TBL] [Abstract][Full Text] [Related]
5. Dramatic tumor response of bulky liver metastases following treatment with CPT-11 and a chronomodulated 4-day infusion of 5-fluorouracil, folinic acid and oxaliplatin every 2 weeks in a colorectal cancer patient.
Gornet JM; Azoulay D; Lévi F; Yovine A; Misset JL; Goldwasser F
Anticancer Drugs; 2000 Apr; 11(4):263-8. PubMed ID: 10898541
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer.
Kemeny N; Jarnagin W; Gonen M; Stockman J; Blumgart L; Sperber D; Hummer A; Fong Y
J Clin Oncol; 2003 Sep; 21(17):3303-9. PubMed ID: 12947066
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
Rosati G; Tucci A; Rinaldi A; Colarusso D; Pizza C; Reggiardo G; Manzione L
Oncology; 2004; 66(5):371-8. PubMed ID: 15331924
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy in patients with stage IV colorectal cancer: a comparison of histological response in liver metastases, primary tumors, and regional lymph nodes.
Gervaz P; Rubbia-Brandt L; Andres A; Majno P; Roth A; Morel P; Mentha G
Ann Surg Oncol; 2010 Oct; 17(10):2714-9. PubMed ID: 20405223
[TBL] [Abstract][Full Text] [Related]
9. Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies.
Lorenz M; Staib-Sebler E; Gog C; Proschek D; Jauch KW; Ridwelski K; Hohenberger W; Gassel HJ; Lehmann U; Vestweber KH; Padberg W; Zamzow K; Müller HH
Zentralbl Chir; 2003 Feb; 128(2):87-94. PubMed ID: 12632273
[TBL] [Abstract][Full Text] [Related]
10. [Liver resection after downstaging with neoadjuvant chemotherapy for "unresectable" colorectal metastases].
Frena A; Martin F; La Guardia G; Vezzali N; Bonatti G; Stocker J; Graiff C
Chir Ital; 2004; 56(3):351-7. PubMed ID: 15287631
[TBL] [Abstract][Full Text] [Related]
11. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis.
Ji JH; Park SH; Lee J; Kim TW; Hong YS; Kim KP; Kim SY; Baek JY; Kang HJ; Shin SJ; Shim BY; Park YS
Cancer Chemother Pharmacol; 2013 Jul; 72(1):223-30. PubMed ID: 23689915
[TBL] [Abstract][Full Text] [Related]
12. Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research Group.
Ho WM; Ma B; Mok T; Yeo W; Lai P; Lim R; Koh J; Wong YY; King A; Leow CK; Chan AT
Med Oncol; 2005; 22(3):303-12. PubMed ID: 16110141
[TBL] [Abstract][Full Text] [Related]
13. Cetuximab in combination with 5-fluorouracil, leucovorin and irinotecan as a neoadjuvant chemotherapy in patients with initially unresectable colorectal liver metastases.
Min BS; Kim NK; Ahn JB; Roh JK; Kim KS; Choi JS; Cha SH; Kim H
Onkologie; 2007 Dec; 30(12):637-43. PubMed ID: 18063876
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant treatment with weekly high-dose 5-Fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer.
Wein A; Riedel C; Brückl W; Merkel S; Ott R; Hanke B; Baum U; Fuchs F; Günther K; Reck T; Papadopoulos T; Hahn EG; Hohenberger W
Oncology; 2003; 64(2):131-8. PubMed ID: 12566910
[TBL] [Abstract][Full Text] [Related]
15. Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases.
Pietrantonio F; Di Bartolomeo M; Cotsoglou C; Mennitto A; Berenato R; Morano F; Coppa J; Perrone F; Iacovelli R; Milione M; Alessi A; Vaiani M; Bossi I; Ricchini F; Scotti M; Caporale M; Bajetta E; de Braud F; Mazzaferro V
Clin Colorectal Cancer; 2017 Sep; 16(3):e191-e198. PubMed ID: 27979717
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant treatment with weekly high-dose 5-fluorouracil as a 24h-infusion, folinic acid and biweekly oxaliplatin in patients with primary resectable liver metastases of colorectal cancer: long-term results of a phase II trial.
Boxberger F; Albrecht H; Konturek PC; Reulbach U; Maennlein G; Meyer T; Hohenberger W; Hahn EG; Wein A
Med Sci Monit; 2010 Feb; 16(2):CR49-55. PubMed ID: 20110914
[TBL] [Abstract][Full Text] [Related]
17. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.
Taïeb J; Artru P; Paye F; Louvet C; Perez N; André T; Gayet B; Hebbar M; Goebel FM; Tournigand C; Parc R; de Gramont A
J Clin Oncol; 2005 Jan; 23(3):502-9. PubMed ID: 15659495
[TBL] [Abstract][Full Text] [Related]
18. Multiple-target chemotherapy (LV-modulated 5-FU bolus and continuous infusion, oxaliplatin, CPT- 11) in advanced 5-FU-refractory colorectal cancer: MTD definition and efficacy evaluation. A phase I-II study.
Bonetti A; Zaninelli M; Durante E; Fraccon AP; Franceschi T; Pasini F; Zustovich F; Brienza S
Tumori; 2006; 92(5):389-95. PubMed ID: 17168430
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy for colorectal cancer prior to liver resection for colorectal cancer hepatic metastases does not adversely affect peri-operative outcomes.
Sahajpal A; Vollmer CM; Dixon E; Chan EK; Wei A; Cattral MS; Taylor BR; Grant DR; Greig PD; Gallinger S
J Surg Oncol; 2007 Jan; 95(1):22-7. PubMed ID: 17066435
[TBL] [Abstract][Full Text] [Related]
20. Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study.
Calvo E; Cortés J; Rodríguez J; Fernández-Hidalgo O; Rebollo J; Martín-Algarra S; García-Foncillas J; Martínez-Monge R; de Irala J; Brugarolas A
Clin Colorectal Cancer; 2002 Aug; 2(2):104-10. PubMed ID: 12453325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
